Mizuho Cuts Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) Price Target to $18.00

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) had its price target lowered by Mizuho from $20.00 to $18.00 in a report published on Wednesday morning,Benzinga reports. Mizuho currently has an outperform rating on the stock.

Other research analysts have also issued research reports about the stock. HC Wainwright cut their target price on shares of Senseonics Holdings, Inc. Common Stock from $18.50 to $14.00 and set a “buy” rating for the company in a research report on Tuesday, May 12th. Stifel Nicolaus lowered their price target on Senseonics Holdings, Inc. Common Stock from $9.00 to $8.00 and set a “hold” rating on the stock in a research report on Monday, May 11th. Finally, Weiss Ratings lowered Senseonics Holdings, Inc. Common Stock from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 28th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $17.20.

Senseonics Holdings, Inc. Common Stock Stock Down 0.6%

NASDAQ:SENS opened at $5.11 on Wednesday. The company has a 50 day moving average price of $6.11. The company has a debt-to-equity ratio of 1.05, a quick ratio of 3.19 and a current ratio of 3.51. Senseonics Holdings, Inc. Common Stock has a 12 month low of $4.79 and a 12 month high of $12.51. The company has a market capitalization of $213.60 million, a price-to-earnings ratio of -2.56 and a beta of 0.99.

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.06). Senseonics Holdings, Inc. Common Stock had a negative return on equity of 129.97% and a negative net margin of 213.87%.The firm had revenue of $11.71 million for the quarter. Research analysts predict that Senseonics Holdings, Inc. Common Stock will post -2.38 EPS for the current fiscal year.

Insider Buying and Selling at Senseonics Holdings, Inc. Common Stock

In other Senseonics Holdings, Inc. Common Stock news, Director Douglas A. Roeder bought 22,686 shares of the stock in a transaction that occurred on Tuesday, May 12th. The shares were acquired at an average price of $5.56 per share, with a total value of $126,134.16. Following the completion of the purchase, the director directly owned 144,635 shares in the company, valued at $804,170.60. The trade was a 18.60% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 4.70% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Cetera Investment Advisers bought a new stake in Senseonics Holdings, Inc. Common Stock in the first quarter valued at $85,000. Captrust Financial Advisors bought a new position in shares of Senseonics Holdings, Inc. Common Stock during the fourth quarter valued at $77,000. Hudson Bay Capital Management LP bought a new position in shares of Senseonics Holdings, Inc. Common Stock during the fourth quarter valued at $85,000. GSK plc acquired a new stake in shares of Senseonics Holdings, Inc. Common Stock in the 4th quarter valued at $60,000. Finally, Ausdal Financial Partners Inc. boosted its stake in shares of Senseonics Holdings, Inc. Common Stock by 50.0% in the 3rd quarter. Ausdal Financial Partners Inc. now owns 105,000 shares of the company’s stock valued at $46,000 after purchasing an additional 35,000 shares in the last quarter. Institutional investors own 12.36% of the company’s stock.

About Senseonics Holdings, Inc. Common Stock

Senseonics Holdings, Inc develops and commercializes long-term implantable continuous glucose monitoring (CGM) systems for people with diabetes. The company’s primary product family is the Eversense system, which combines a small subcutaneously implanted sensor, a removable external transmitter, and companion smartphone applications to provide continuous glucose readings and alerts. Senseonics positions its technology as an alternative to wearable patch-style CGMs by offering multi-month sensor longevity and on-body vibration alerts delivered through the transmitter.

Senseonics supports clinical and commercial activities that include research and development, regulatory engagement, manufacturing and distribution, and training for healthcare providers who perform sensor insertion and removal.